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Background: We present a case of a patient initially presenting with multifocal choroiditis (MFC) in one eye. She
subsequently developed lesions most consistent with punctate inner choroidopathy (PIC) in the contralateral eye,
followed by acute vision loss from retrobulbar optic neuropathy. Optic neuropathy has been well described in the
setting of MFC. There is, however, only one report of its association with PIC. Punctate inner choroidopathy and
MFC have many similarities, with visual loss generally resulting from choroidal neovascularization. In this case, the
patient had significant visual loss from presumed retrobulbar optic neuropathy.
Findings: The patient responded well to immunomodulation with subsequent return of vision to baseline.
Conclusions: Multifocal choroiditis and punctate inner choroidopathy may be a spectrum of the same disease with
many overlapping presentations, including optic neuropathy. Good visual recovery and remission were attained
with mycophenolate mofetil and systemic corticosteroid treatment.
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This report describes a case of recalcitrant posterior uve-
itis with characteristics of both multifocal choroiditis
(MFC) and punctate inner choroidopathy (PIC), which
was subsequently complicated by optic neuropathy in
the eye with lesions most consistent with PIC.
Optic neuropathy appears to be more commonly asso-
ciated with MFC than PIC [1,2]. Optic neuropathy in pa-
tients with MFC has been well described as presenting
with optic disc edema or pallor, with a typical response
to steroids resulting in an increase in visual performance
[2]. A review of the literature identified only one case re-
port of the association of PIC and optic neuropathy [1].
There remains controversy whether PIC and MFC (and
perhaps other white dot syndromes) represent similar dis-
ease processes on a continuum [3,4]. The present case de-
scribes a patient presenting with lesions characteristic of
multifocal choroiditis in one eye and punctate inner
choroidopathy in the contralateral eye. Optic neuropathy* Correspondence: pdayani@gmail.com
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in any medium, provided the original work is pwas the primary cause of visual loss in the eye with lesions
more typical of those seen in PIC. The presentation of
optic neuropathy (ON), more commonly seen with MFC,
demonstrated in the eye with uveitic characteristics of
PIC, further unifies these disorders. In addition to
reporting this rare association, this case highlights the
overlap of PIC and MFC by demonstrating gradual pro-
gression and enlargement of the chorioretinal lesions,
which were initially more typical of those seen in PIC.
Case report
The patient is a 30-year-old myopic woman (approximate
refractive error of −7.50 diopter) with a history of recurrent
macular and midperipheral chorioretinal lesions typical of
MFC (without vitritis) for 5 years in the right eye (see
Figure 1 - OD (oculus dexter), 2007 to 2011). She had been
treated with oral and periocular steroids for exacerbations.
After several years, the inflammatory process in the right
eye underwent a quiescent phase without the development
of any further lesions. At that time, the best-corrected vis-
ual acuity (BCVA) was 20/50 in the right eye and 20/20 in
the left eye. Over the ensuing 3 years, recurrent inflamma-
tion was observed in the left eye only (see Figure 1 - OSOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Macular Lesions 2007-2011. Initial evolution of chorioretinal lesions over a 4-year period to disease activity (fourth frame OS) then
quiescent on treatment in 2010: disease stability in 2007, 2008, 2009, 2010 (active disease), and 2011 (quiescent disease). Notice that OD remains
stable throughout, and OS remains stable until a considerable increase of activity of lesions occurs in the 2010 photos but returns to quiescent
lesions in 2011.
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were smaller and more typical of those seen in PIC
(see Figure 1 - OS and Figure 2a). Although nasal and
midperipheral lesions were seen in the right eye, only
macular lesions were observed in the left eye. A typical
systemic evaluation was performed and was negative for
any specific inflammatory or infectious process (includingFigure 2 Comparative evolution of PIC lesions OS. (a) Fundus and red-
(SD-OCT), and autofluorescence at baseline of our report (early 2010). (b) A
when the vision have fallento CF. Note the new lesions (regions indicated
retinal pigment epithelium (RPE)/photoreceptor alterations (arrow) on SD-O
is noted. (c) Most recent images following treatment demonstrating regres
SD-OCT image showing RPE/photoreceptor loss in the areas of previously atuberculosis, Lyme, syphilis, Bartonella, sarcoid, and hu-
man leukocyte antigen (HLA) A-29 and B-27).
In 2010, the patient presented with vision changes for
3 days in her left eye and reduced visual acuity to 20/25.
No cellular inflammation was noted. Dilated posterior
segment examination showed an increase in macular
chorioretinal lesions. Despite a strong recommendation forfree photograph, spectral domain optical coherence tomography
ctive disease with multiple new lesions in the left eye 3 months later
by arrows) on color photograph and autofluorescent image, and
CT image during active disease. No optic nerve edema or hyperemia
sion of some of the smaller lesions and enlargement of others.
ctive lesions (arrow).
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local treatment, and a posterior subtenon's triamcinolone
injection (40 mg) was administered.
Three days later, the patient returned with progressive
‘blurred vision and not much pain’. The visual acuity was
reduced to 20/80, but the fundus examination was un-
changed. An intravitreal injection of Triesense (2 mg) was
administered, and the patient was started on oral prednis-
one of 80 mg daily and mycophenolate mofetil 1 g BID.
The rheumatology service was consulted.
Eleven days later, the patient returned with BCVA of
counting fingers in her left eye. The anterior chamber was
quiet in both eyes, and the anterior vitreous showed 0.5+
cells in the affected eye. Dilated ophthalmoscopy did not
reveal any change from the prior visits. No optic disc
edema or pallor was noted (see Figure 2b). The patient
had a fluorescein allergy which prevented the acquisition
of fluorescein images. Indocyanine green angiography was
obtained, which demonstrated lesions corresponding to
those seen on clinical examination, optical coherence tom-
ography, and fundus autofluorescence. There were no new
chorioretinal lesions or choroidal neovascularization. The
patient was pharmacologically dilated, preventing an
evaluation for an afferent papillary defect.
Extensive ancillary testing was performed including: a
Goldman visual field which revealed an enlarged blind-
spot in the left eye; absent color vision in the left eye
(unable to see test plate); full field electroretinogram
(ERG, normal in both eyes); multifocal ERG (abnormal
left eye greater than right eye); and visual evoked poten-
tials (VEP) (normal in the right eye, very low amplitude
with normal implicit times in the left eye). The series of
testing implied an optic nerve conduction deficit for the
left eye.
The patient was admitted to the hospital for intravenous
solumedrol (1 g daily for 3 days) and was evaluated by
rheumatology, neurology, and neuroophthalmology. The
visual loss remained stable with a slight discomfort to the
eye during her admission. Magnetic resonance images of
brain and spine, with and without contrast, and a lumbar
puncture were unremarkable. Images of the optic nerve
from the brain MRI did not demonstrate any abnormality.
Additional laboratory testing was performed (including
extensive rheumatologic and coagulopathic studies),
which provided no evidence of a systemic or local
etiology for the optic neuropathy. The patient was
discharged from the hospital on mycophenolate mofetil
and oral steroids taper.
Follow-up examination 1 month after discharge dem-
onstrated that the BCVA had improved to 20/40 in the
left eye but detection of color plates remained absent.
The visual acuity continued to improve over the subse-
quent 2 months to 20/25 without any improvement in
color vision.One year following the initial episode of optic neur-
opathy, the patient's uveitis was stable on mycophenolate
500 mg twice daily. BCVA remained stable at 20/60 for
the right eye and 20/20 for the left eye, and color plates
were now full for both eyes. Fundus examination shows
enlargement of the previous chorioretinal lesions (see
Figure 2c).
Discussion
Punctate inner choroidopathy is a bilateral uveitic dis-
ease, primarily affecting young myopic women first de-
scribed by Watzke in 1984 [5,6]. The primary etiology of
this inflammatory condition remains unclear, but an as-
sociation with Epstein-Barr virus and with HLA-DR2
positivity have been reported [7,8]. The disease typically
presents with yellow-white chorioretinal lesions at the
level of the choroid, not associated with vitritis. As the
lesions evolve, they leave a depigmented halo and appear
‘punched out’ similar to lesions observed in ocular his-
toplasmosis syndrome (OHS).
Multifocal choroiditis is also a bilateral condition typic-
ally affecting myopic women that presents with punched
out posterior pole and peripheral chorioretinal scars with
juxtapapillary scarring (also similar to OHS) [4]. It was
first described by Nozik and Dorsch, and later by Dreyer
and Gass, and can be associated with panuveitis and
snowbanking, choroidal neovascularization, and visual
field defects [9-11]. MFC is not associated with any HLA
specificity and is often associated with vitreous and ante-
rior chamber cells.
Many features of this case are typical of both MFC and
PIC. Central visual loss in both PIC and MFC, when
present, is usually from subretinal fibrosis secondary to
choroidal neovascular membranes [5,11,12]. The aspect of
this case that is most unique is the sudden severe visual
loss without evidence of choroidal neovascularization, fo-
veal chorioretinal lesions, or cystoid macular edema. The
initial increase in the chorioretinal lesions and the subtle
decrease in visual acuity (to 20/25) were consistent with
active inflammatory disease observed clinically. The sud-
den further loss of central vision (to count fingers), the
loss of color vision, the low amplitude of the VEP in the
affected eye, and the absence of any new macular lesions
led us to believe that the dramatic vision loss was a result
of an anterior optic pathway process independent of the
lesion activity.
The use of mycophenolate has been shown to reduce
the proliferation of B and T lymphocytes through inhib-
ition of purine biosynthesis and can be efficacious in the
management of ocular inflammation, including PIC
[13,14]. When local therapy became insufficient in
the management of our patient, initiation of systemic
immunomodulation was effective in controlling the in-
flammation and maintaining long-term quiescence.
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ferent pupillary defect was not noted as either being
present or absent and the MRI study did not specifically
review the optic nerves. The presumed retrobulbar optic
neuropathy, however, did demonstrate a typical course
and response to treatment. Retrobulbar ON in the set-
ting of PIC has been reported just once by Yamada et al.
[1]. This complication, however, is well established in
the setting of MFC and has been shown to be steroid re-
sponsive [1,2].
The co-presentation of posterior segment lesions char-
acteristic of both PIC and MFC, as well as the subse-
quent development of optic neuropathy in this patient,
is unique. These observations further support the possi-
bility that PIC and MFC are variable presentations of the
same disease process, as opposed to discrete clinical
entities. The patient initially responded well to local
therapy but eventually required a steroid-sparing agent
for long-term inflammatory control.
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